Long-term opioid use may not increase risk of Alzheimer's

Image
ANI Washington D.C. [U.S.A.]
Last Updated : Oct 25 2017 | 12:02 PM IST

Myth busted! Long-term use of powerful pain-relieving drugs is not associated with an increased risk of Alzheimer's disease, shows a recent study.

According to the study, long-term use of opioids, which are powerful pain relieving drugs that act on the nervous system, is not associated with an increased risk of Alzheimer's disease.

The researchers from the University of Eastern Finland did not find any risk - neither for the long-term use nor for higher cumulative doses.

The team claims that the study is the most extensive one conducted on the topic so far.

The team conducted a nationwide register-based MEDALZ study and included 70,718 persons diagnosed with the Alzheimer's disease in Finland during 2005-2011, as well as 282,862 control persons.

The Opioid use may also lead to addiction or tolerance to pain-relieving effects.

Opioid use was compared between Finnish persons with the Alzheimer's disease and their control persons without the disease.

A previous study from the U.S. reported an association between high cumulative doses of opioids and an increased risk of dementia, but the Finnish study does not confirm this finding.

However, several adverse effects are related to opioid use, such as drowsiness and reduced alertness and for this reason, the opioid use should be restricted to the most severe pain conditions only.

The research appeared in the Pain Medicine journal.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 25 2017 | 12:02 PM IST

Next Story